Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Dedifferentiated liposarcoma (DDLS) is a rare but aggressive cancer with high recurrence and low response rates to targeted therapies. Increasing treatment efficacy may require combinations of targeted agents that counteract the effects of multiple abnormalities. To identify a possible multicomponent therapy, we performed a combinatorial drug screen in a DDLS-derived cell line and identified cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets. We measured the phosphorylation of multiple proteins and cell viability in response to systematic drug combinations and derived computational models of the signaling network. These models predict that the observed synergy in reducing cell viability with CDK4 and IGF1R inhibitors depends on the activity of the AKT pathway. Experiments confirmed that combined inhibition of CDK4 and IGF1R cooperatively suppresses the activation of proteins within the AKT pathway. Consistent with these findings, synergistic reductions in cell viability were also found when combining CDK4 inhibition with inhibition of either AKT or epidermal growth factor receptor (EGFR), another receptor similar to IGF1R that activates AKT. Thus, network models derived from context-specific proteomic measurements of systematically perturbed cancer cells may reveal cancer-specific signaling mechanisms and aid in the design of effective combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A combinatorial drug screen in dedifferentiated liposarcoma cell lines also identified CDK4 and IGF1R as synergistic drug targets.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [122]
In the citing paper
“The models predicted that the observed synergy of CDK4 and IGF1R inhibitors depends on activated AKT; consistent with this prediction, combined inhibition of CDK4 and IGF1R cooperatively suppressed activation of proteins within the AKT pathway (122).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“For this study, we measured synergy by the Loewe additivitybased combination index (CI) score, which can handle cases where two drugs act on targets regulating a common pathway (33) (Fig 1A).”
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“The AKT pathway is one of the major downstream pathways of IGF1R (46), and indeed we found that IGF1R inhibition with R1507 or NVP-AEW541 represses phosphorylation of AKT and downstream members of the AKT/mTOR pathway (p70S6K, S6).”
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,708
PID: the Pathway Interaction Database
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., & Buetow, K. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn653 · Cited by 1,603
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
Self-citationCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · cited 4×
“Second, in agreement with the parallel pathway hypothesis model for drug synergy (17, 21, 22), the most Miller et al.”
InfluentialBlackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Generalization of back-propagation to recurrent neural networks
Pineda, F. J. (1987) · Physical Review Letters · doi:10.1103/physrevlett.59.2229 · Cited by 931 · cited 1×
“after parameter refinement with gradient descent (57) and ranking by performance metrics on the training set, and only these 100 low error models are used for direct simulation and prediction.”
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., & Mills, G. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413597 · Cited by 830
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 1×
“In the case of limited initial treatment response (referred to as primary resistance), combination therapy with two or more targeted drugs improves efficacy (11, 12), such as the combination of the HER2-specific antibody trastuzumab with the receptor tyrosine kinase (RTK) inhibitor Lapatinib in HER2-positive metastati…”
Differentiation Stage-Specific Inhibition of the Raf-MEK-ERK Pathway by Akt
Rommel, C., Clarke, B. A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., & Glass, D. J. (1999) · Science · doi:10.1126/science.286.5445.1738 · Cited by 758
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Self-citationTibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Chung, J., Uchida, E., Grammer, T. C., & Blenis, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6508 · Cited by 620
Physicochemical modelling of cell signalling pathways
Aldridge, B. B., Burke, J. M., Lauffenburger, D. A., & Sorger, P. K. (2006) · Nature Cell Biology · doi:10.1038/ncb1497 · Cited by 592
Systems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570 · cited 3×
“The CI score is well suited for estimating effects of drug combinations as it is based on the concept of dosesubstitution and can handle cases where the two drugs are the same, act on the same target, or act on targets converging in a common pathway (15).”
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Maki, R. G., D'Adamo, D. R., Keohan, M. L., Saulle, M., Schuetze, S. M., Undevia, S. D., Livingston, M. B., Cooney, M. M., Hensley, M. L., Mita, M. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4495 · Cited by 569
Self-citationPlectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II
Schneider, T., Kruse, T., Wimmer, R., Wiedemann, I., Sass, V., Pag, U., Jansen, A., Nielsen, A. K., Mygind, P. H., Raventós, D. S., et al. (2010) · Science · doi:10.1126/science.1185723 · Cited by 550
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 518
Self-citationResistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Regulation of Protein Kinase B/Akt-Serine 473 Phosphorylation by Integrin-linked Kinase
Persad, S., Attwell, S., Gray, V., Mawji, N., Deng, J. T., Leung, D., Yan, J., Sanghera, J., Walsh, M. P., & Dedhar, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102940200 · Cited by 497
Role of Phosphatidylinositol Kinase in PDGF Receptor Signal Transduction
Coughlin, S. R., Escobedo, J. A., & Williams, L. T. (1989) · Science · doi:10.1126/science.2466336 · Cited by 495
IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms
Mohan, S., & Baylink, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750019 · Cited by 444
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Self-citationConnell-Crowley, L., Harper, J. W., & Goodrich, D. W. (1997) · Molecular Biology of the Cell · doi:10.1091/mbc.8.2.287 · Cited by 407
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Self-citationActivation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues.
Zheng, C. F., & Guan, K. L. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06361.x · Cited by 398
Proliferation, But Not Growth, Blocked by Conditional Deletion of 40 S Ribosomal Protein S6
Volarević, S., Stewart, M. J., Ledermann, B., Zilberman, F., Terracciano, L., Montini, E., Grompe, M., Kozma, S. C., & Thomas, G. (2000) · Science · doi:10.1126/science.288.5473.2045 · Cited by 373
Liposarcoma: New entities and evolving concepts
Dei Tos, A. (2000) · Annals of Diagnostic Pathology · doi:10.1053/adpa.2000.8133 · Cited by 369
Differential sensitivity of liposarcoma subtypes to chemotherapy
Jones, R. L., Fisher, C., Al-Muderis, O., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.023 · Cited by 354
Functional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Drug interactions and the evolution of antibiotic resistance
Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2133 · Cited by 350 · cited 3×
“Second, in agreement with the parallel pathway hypothesis model for drug synergy (17, 21, 22), the most Miller et al.”
Zheng, C. F., & Guan, K. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82142-1 · Cited by 330
Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B
Scheid, M. P., Marignani, P. A., & Woodgett, J. R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6247-6260.2002 · Cited by 329
Systematic exploration of synergistic drug pairs
Cokol, M., Chua, H. N., Tasan, M., Mutlu, B., Weinstein, Z. B., Suzuki, Y., Nergiz, M. E., Costanzo, M., Baryshnikova, A., Giaever, G., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.71 · Cited by 315
Dong, G., Chen, Z., Li, Z. Y., Yeh, N. T., Bancroft, C. C., & Waes, C. V. (2001) · PubMed · Cited by 309
Haynes, M. P., Li, L., Sinha, D., Russell, K. S., Hisamoto, K., Baron, R., Collinge, M., Sessa, W. C., & Bender, J. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210828200 · Cited by 304
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Ceramide Activates the Stress-activated Protein Kinases
Westwick, J. K., Bielawska, A. E., Dbaibo, G., Hannun, Y. A., & Brenner, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.22689 · Cited by 303
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity
Fedele, M., Visone, R., De Martino, I., Troncone, G., Palmieri, D., Battista, S., Ciarmiello, A., Pallante, P., Arra, C., Melillo, R. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.024 · Cited by 273
Lorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., Radford, J. A., Van Glabbeke, M. M., Kirkpatrick, A., Hogendoorn, P. C. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7717 · Cited by 256
Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
Crago, A. M., & Singer, S. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834796e6 · Cited by 252
Self-citationSinger, S., Socci, N. D., Ambrosini, G., Sambol, E., Decarolis, P., Wu, Y., O'Connor, R., Maki, R., Viale, A., Sander, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0584 · Cited by 250
Self-citationZhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609370104 · Cited by 248
Ligand-Specific c-Fos Expression Emerges from the Spatiotemporal Control of ErbB Network Dynamics
Nakakuki, T., Birtwistle, M. R., Saeki, Y., Yumoto, N., Ide, K., Nagashima, T., Brusch, L., Ogunnaike, B. A., Okada-Hatakeyama, M., & Kholodenko, B. N. (2010) · Cell · doi:10.1016/j.cell.2010.03.054 · Cited by 241
Chugh, R., Wathen, J. K., Maki, R. G., Benjamin, R. S., Patel, S. R., Myers, P. A., Priebat, D. A., Reinke, D. K., Thomas, D. G., Keohan, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5054 · Cited by 234
Stat Protein Transactivation Domains Recruit p300/CBP through Widely Divergent Sequences
Paulson, M., Pisharody, S., Pan, L., Levy, D. E., Guadagno, S., & Mui, A. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25343 · Cited by 234
Non-parametric quantification of protein lysate arrays
Hu, J., He, X., Baggerly, K. A., Coombes, K. R., Hennessy, B. T. J., & Mills, G. B. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm283 · Cited by 224
Bornancin, F., & Parker, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3544 · Cited by 191
Perturbation Biology: Inferring Signaling Networks in Cellular Systems
Molinelli, E. J., Korkut, A., Wang, W., Miller, M. L., Gauthier, N. P., Jing, X., Kaushik, P., He, Q., Mills, G., Solit, D. B., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003290 · Cited by 187
Self-citationModels from experiments: combinatorial drug perturbations of cancer cells
Nelander, S., Wang, W., Nilsson, B., She, Q., Pratilas, C., Rosen, N., Gennemark, P., & Sander, C. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.53 · Cited by 187
Self-citationAdams, P. D., Li, X., Sellers, W. R., Baker, K. B., Leng, X., Harper, J. W., Taya, Y., & Kaelin, W. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1068 · Cited by 187
Principles and Strategies for Developing Network Models in Cancer
Pe'er, D., & Hacohen, N. (2011) · Cell · doi:10.1016/j.cell.2011.03.001 · Cited by 182
Motwani, M., Delohery, T. M., & Schwartz, G. K. (1999) · PubMed · Cited by 173
Self-citationLehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Dufner, A., Andjelkovic, M., Burgering, B. M. T., Hemmings, B. A., & Thomas, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4525 · Cited by 171
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170 · cited 1×
“DNA copy number profiling was performed using the 244K Agilent array-comparative genomics hybridization (aCGH) platform, and standard circular binary segmentation (R/bioconductor DNAcopy library) was analyzed using the RAE algorithm (53).”
MethodSelf-citationConverting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
Assessment of Cell Proliferation with Resazurin-Based Fluorescent Dye
Czekanska, E. M. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-108-6_5 · Cited by 167
Bayesian Network Analysis of Signaling Networks: A Primer
Pe'er, D. (2005) · Science's STKE · doi:10.1126/stke.2812005pl4 · Cited by 165
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Ali, S. M., & Sabatini, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500125200 · Cited by 139
Beeser, A. E., Jaffer, Z. M., Hofmann, C., & Chernoff, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502306200 · Cited by 137
EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis
Vindis, C., Cerretti, D. P., Daniel, T. O., & Huynh‐Do, U. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302073 · Cited by 117
Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli
Chatterjee, M. S., Purvis, J. E., Brass, L. F., & Diamond, S. L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1642 · Cited by 113
Azmi, A. S., Wang, Z., Philip, P. A., Mohammad, R. M., & Sarkar, F. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0642 · Cited by 100
Acquired Radioresistance of Cancer and the AKT/GSK3β/cyclin D1 Overexpression Cycle
Shimura, T. (2011) · Journal of Radiation Research · doi:10.1269/jrr.11098 · Cited by 97
Stover, D. R., Furet, P., & Lydon, N. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12481 · Cited by 92
Valovka, T., Verdier, F., Cramer, R., Zhyvoloup, A., Fenton, T. R., Rebholz, H., Wang, M., Gzhegotsky, M. R., Lutsyk, A. D., Matsuka, G. K., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.852-863.2003 · Cited by 81
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 80
Crago, A. M., Socci, N. D., DeCarolis, P., O'Connor, R., Taylor, B. S., Qin, L.-X., Antonescu, C. R., & Singer, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2820 · Cited by 76
Self-citationMolecular crosstalk between p70S6k and MAPK cell signaling pathways
Lehman, J. A., & Gómez-Cambronero, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00238-3 · Cited by 75
Farha, M. A., & Brown, E. D. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.06.008 · Cited by 72
Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity
Xu, W., Yuan, X., Beebe, K. E., Xiang, Z., & Neckers, L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00899-06 · Cited by 70
Gosens, R., Dueck, G., Rector, E. S., Nunes, R. O., Gerthoffer, W. T., Unruh, H. W., Zaagsma, J., Meurs, H., & Halayko, A. J. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00346.2007 · Cited by 68
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
Olmos, D., Martins, A. S., Jones, R. L., Alam, S. M., Scurr, M. R., & Judson, I. R. (2011) · Sarcoma · doi:10.1155/2011/402508 · Cited by 63
Yogi, Á., Callera, G. E., Montezano, A. C. I., Aranha, A. B., Tostes, R. C., Schiffrin, E. L., & Touyz, R. M. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.146746 · Cited by 49
Motwani, M., Li, X., & Schwartz, G. K. (2000) · PubMed · Cited by 40
Self-citationKuemmerle, J. F. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00345.2005 · Cited by 38
Spatial Normalization of Reverse Phase Protein Array Data
Kaushik, P., Molinelli, E. J., Miller, M. L., Wang, W., Korkut, A., Liu, W., Ju, Z., Lu, Y., Mills, G. B., & Sander, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097213 · Cited by 27
Self-citationMur, C., Arribas, M., Benito, M., & Valverde, Á. M. (2003) · Endocrinology · doi:10.1210/en.2002-220828 · Cited by 26
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets
Flaherty, K. T. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9488-y · Cited by 15
Cited by
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
What is synergy? The Saariselkä agreement revisited
Tang, J., Wennerberg, K., & Aittokallio, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00181 · Cited by 217
Metadata
- Authors
- Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., Schwartz, G. K., & Sander, C.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Miller, Martin L.
- Molinelli, Evan J.
- Singer, Samuel
- Schwartz, Gary K.
- Sander, Chris
- ORCID
- Venue
- Science Signaling
- Published
- 2013-09-24
- Volume
- 6
- Issue
- 294
- Pages
- ra85-ra85
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- PMC
- PMC4000046
- OpenAlex
- W2129662907
- Cited by
- 86
- References
- 97
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 12 · 2014: 9 · 2013: 2
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32gm083937-09)
- National Cancer Institute (U54CA148967, P50CA140146, U54CA143798, P30CA008748)
- National Institute of General Medical Sciences (1T32GM083937, GM 103504, T32-GM083937, P41GM103504)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- dedifferentiated liposarcoma, CDK4, IGF-1 receptor, drug synergy, combination therapy, Akt signaling, EGFR, signaling network modeling, protein phosphorylation, cell viability, targeted therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Computer Simulation, Drug Screening Assays, Antitumor, Drug Synergism, Humans, Liposarcoma, Models, Biological, Signal Transduction, Drug Delivery Systems, Receptor, IGF Type 1, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.